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Poster Session I S315served as controls. Using samples from over 20 patients in four
groups, we first conducted a discovery study to identify peptide vari-
ables that were significant across disease development (control vs.
IPS) and time (day 0 vs. day of Dx or day 14 for controls). This re-
vealed a set of 81 IPS-associated proteins that were verified by a num-
ber of methods, analyzed by ingenuity pathway analysis (IPA) and
mapped to relevant immune pathways. IPA underscored a significant
contribution of the acute phase response (TNFa / IL-6) signaling
pathway during disease progression and revealed striking similarities
between inflammation engendered during IPS in humans and mice.
In the second verification analysis, we used only samples collected on
day 0 from a larger cohort of patients to identify proteins that were
effective variables for patient stratification. Identified peptides were
subjected to predictive model building using the Ishwaran&Rao ap-
proach, which identified a set of robust plasma proteomic markers
that could 1) predict the development of IPS, and 2) identify individ-
uals who would ultimately respond to etanercept therapy. Analysis
also revealed a number of novel proteins including attractin, lumican
and LBP (the expression of which was verified by ELISA) that were
significant in the discovery analysis and classifiers for disease devel-
opment and or response to therapy. In sum, data generated in this
translational research endeavor confirm previous clinical and exper-
imental observations, provide new insights into the pathophysiology
of IPS and identify a set of robust markers predictive for disease pro-
gression and response to therapy. As anti-TNF therapies are being
developed as treatment for GVHD and other immune-mediated dis-
orders, these results uncover a set of robust markers for patient strat-
ification as a basis for individualized therapy that is ripe for further
development.296
CMX001 AS THERAPY FOR SEVERE ADENOVIRUS INFECTIONS IN IMMU-
NOCOMPROMISED PEDIATRIC PATIENTS: SINGLE EXPERIENCE IN 5 PA-
TIENTS
Grimley, M.S.1, Marsh, R.A.1, Bleesing, J.J.1, Mehta, P.A.1,
Jodele, S.A.1, Myers, K.M.1, Kumar, A.1, Jordan, M.B.1,
Edwards, S.L.1, Kennedy, R.1, Wilhelm, J.1, Painter, W.2,
Anderson, M.2, Filipovich, A.H.1, Davies, S.M.1 1Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH; 2Chimerix, Inc., Durham, NC
Background: Adenovirus infection is a serious and often fatal com-
plication in immunocompromised patients. There are currently no
FDA-approved therapies for adenovirus infection. Cidofovir has
been reported to have variable efficacy in treating Adenovirus but
is associated with significant toxicity, especially renal and possible
marrow toxicity. CMX001 is an oral Lipid -Antiviral-Conjugate
that generates high intracellular levels of the active cidofovir-diphos-
phate without evidence of cidofovir-like nephrotoxicity. CMX001 is
under investigation for the prevention of adenovirus disease.
Methods: We report on 5 patients with adenovirus disease treated
with CMX001. Data were available for . 4 weeks of treatment.
The median age was 1.9 years (Range 1.5 -11.8). The preparative
regimen for the transplant patients consisted of Alemtuzumab, Flu-
darabine and Melaphalan. The graft source was bone marrow.Table 1. Patient Characteristics
Patient Diagnosis
Days post HSCT
of ADV detection
Sites of ADV
infection
Viral Load
(copies/ml)
1 SCID N/A Blood and Stool 770 million
2 SCID due to
RAG2 mutation
-7 Blood and Stool 1.2 million
3 FHL 300 Blood, Stool and
Nasal Secretions
32,000
4 XLP/MDS 70 Blood and Stool 89,000
5 XLP 5 Blood and Stool 102,000
SCID: Severe Combined Immunodeficiency; FHL: Familial Hemophagocytic Lym
phoproliferative Disorder; BIW: twice a week; QW: weekly; TMA: ThrombotGVHD prophylaxis was cyclosporine and methylprednisolone.
Virologic response (VR) was defined as 99% drop from baseline or
undetectable adenovirus DNA by PCR in plasma. Patient character-
istics are shown in Table 1.
Results: Adenovirus disease was diagnosed at a median of 38 days
(range -7 to 300) after transplantation. All patients received intrave-
nous cidofovir for a median of 27 days (range 22-47) prior to starting
CMX001. Four of five patients (80%) had a. 1 log drop in viral load
at the end of 1 week of therapy. VRwas seen in all patients with ame-
dian time to achieve VR was 2 weeks (range 1-3). Four patients re-
ceived doses exceeding those currently being studied. No adverse
events felt to secondary to CMX001 were seen with the 4 mg/kg/
doses. Two patients developed diarrhea that was likely related to
CMX001 therapy while receiving the 2 mg/kg/dose twice weekly.
Both patients had resolution of the symptoms when CMX001 was
stopped and were able to resume therapy without recurrence of
symptoms. No other significant side effects were observed.
Discussion: Our data demonstrates that CMX001 has efficacy
against adenoviral infections with a favorable safety profile. In this
critically ill group of patients, morbidity was high which may reflect
that CMX001 is an investigational medicine and was not used as first
line therapy for adenoviral infections in our institution for these pa-
tients. Clinicians caring for immunocompromised individuals with
adenovirus infections should consider early use of CMX001 for se-
vere adenovirus infections.297
PREVALENCE OF VIRAL INFECTIONS IN CHILDREN UNDERGOING FIRST
ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO
YEAR SINGLE CENTER EXPERIENCE
Ozdemir, N., Jodele, S., Myers, K.C., Mehta, P.A., Bleesing, J.J.,
Jordan, M.B., Marsch, R.A., Kumar, A.R., Bellman, D.,
Filipovich, A.H., Davies, S.M., Grimley,M.S. Cincinnati Children’s Hos-
pital Medical Center, Cincinnati, OH
Background: Viral infections are a major cause of morbidity and
mortality in patients receiving allogenic hematopoietic stem cell
transplantation (HSCT).With the introduction of newer condition-
ing regimens, increasing use of reduced intensity protocols and T
cell depletion, the risk of post-transplant viral infections may be in-
creasing and specific high risk groups may need to be identified as
candidates for intensive viral monitoring and pre-emptive strategies.
Here we report our experience of viral infections in children under-
going their first allogenic HSCT from January 2009-December
2010.
Methods: One hundred twenty four patients, median age 4.9 years
(range: 0.2-25.4) were identified and charts retrospectively reviewed.
Ninety-five patients underwent HSCT for non-malignant disease,
29 for malignant disease. Graft source was unrelated donor in 102
(82%) and matched related in 22 (18%). Stem cell source was bone
marrow in 94 (76%), peripheral blood stem cells in 16 (13%) and
cord blood in 14 (11%). Sixty-four patients (35 with non-malignant
disease, 29 with malignant disease) received myeloablative condi-
tioning regimens. Forty-six patients (all with non-malignant disease)Dose of CMX001
Adverse
Events
Current Status/Followup
(months)
4 mg/kg/dose BIW None Died of Disseminated
Aspergillosis infection
4 mg/kg/dose BIW None Alive and Well/ 8 months
1 dose of 4 mg/kg/dose BIW then
11 doses of 2 mg/kg/dose BIW
Diarrhea Died of Progressive
Bronchiolitis Obliterans
5 doses of 4 mg/kg/dose BIW
then 32 doses of 2 mg/kg/dose BIW
Diarrhea Alive and Well/7 months
2 mg/kg/dose BIW None Died of Pulmonary TMA
phohistiocytosis; MDS: Myelodysplastic Syndrome; XLP: X-Linked Lym-
ic Microangiopathy.
Table 1. Viral infections
Viral infections ADV EBV CMV BKV HHV-6
Prevalance 66/124 (53%) 47/124 (38%) 25/124 (20%) 26/48 (54%) 23/77 (30%)
Viremia only (n) 16 35 16 1 7
Disseminated disease (n) 29 9 8 14 4
Reduced-intensity conditioning 39/60 (65%) 19/60 (32%) 13/60 (22%) 7/20 (35%) 14/40 (35%)
Myeloablative conditioning
With ATG 26/55 (47%) 26/55 (47%) 12/55 (22%) 19/26 (73%) 8/32 (25%)
Without ATG 1/9 (11%) 2/9 (22%) 0 (0%) 0/2 (0%) 1/5 (20%)
Fanconi anemia (T-cell depleted) 5/14 (36%) 4/14 (29%) 4/14 (29%) 6/9 (67%) 2/7 (29%)
Median post-HSCT day
of viral detection (range)
26 (0-341) 42 (4-763) 15 (0-78) 36 (13-119) 86 (1-419)
Viremia was defined as the presence of virus in blood. Disseminated infection was defined as virus detection in at least two different organ systems.
N: patients with a specified condition, (%) percentage of patients affected. Myeloablative conditioning regimen: Busulfan/Cyclophosphamide/Anti-
thymocyte Globulin (ATG) or Cyclophosphamide/TBI. Reduced-intensity conditioning regimen:Alemtuzumab/Fludarabine/Melphalan
S316 Poster Session Ireceived a reduced-intensity conditioning (RIC) regimen, 14 Fan-
coni anemia patients received RIC regimen with T-cell depletion
of the graft. All patients were monitored for cytomegalovirus
(CMV), Epstein-Barr virus (EBV), adenovirus (ADV) weekly in
blood by PCR testing until day +100. Human Herpes Virus-6
(HHV-6) and BK virus (BKV) were monitored when clinically indi-
cated. Viral infection is defined a quantitative PCR detection in
blood or qualitative detection in stool, urine, body fluids or relevant
tissue.
Results: Table 1 demonstrates the prevalence and features of most
common viral infections. Overall survival was 70% with viral infec-
tion as the cause of death in 12 patients (10%).
Discussion:Adenovirus and BK virus were themost prevalent infec-
tions, detected in half of the transplant patients with adenovirusmost
likely to be disseminated. The use of Alemtuzumab, ATG and T-cell
depletion is associated with increased risk of viral infection. We ob-
served a higher prevalence of Adenovirus infections compared to
other reports, likely due to high percentage of unrelated donors
and use of Alemtuzumab and ATG in these patients. Our data rein-
force the importance of ADV as a potential pathogen causing a high
rate of disseminated infection in transplant recipients.298
ROMIPLOSTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR
CELL TRANSPLANTATION: RESULTS OF A PILOT STUDY
Voloshin, S.V., Schmidt, A.V., Shuvaev, V.A., Fominykh, M.S.,
Abdulkadyrov, K.M. Russian Research Institute of Haematology and
Transfusiology, Saint-Petersburg, Russian Federation
Introduction: A number of studies have demonstrated that G-CSF
can fasten neutrophil recovery in patients undergoing high-dose che-
motherapy (HDT) and transplantation of autologous peripheral
blood progenitor cells (PBPCT). However, the only measure to cor-
rect post-transplant thrombocytopenia is still donor platelets trans-
fusions. Recently, immune thrombocytopenic purpura management
has changed with introduction of thrombopoietin receptor agonists
(TRA), which were highly effective and safe in such patients. To
date, the only two TRA are available – romiplostim and eltrombo-
pag. It is possible that administration of TRA can significantly alter
clinical course of patients undergoing HDT. To address this ques-
tion, we initiated a pilot study to assess the efficacy of TRA after
HDT with PBPCT.
Patients and Methods: Seven patients (median age, 45 years; range
21-56; 6male and 1 female) suffered from non-Hodgkin’s lymphoma
(n5 2), Hodgkin’s lymphoma (n5 2) and multiple myeloma (n5 3)
were treated with HDT and PBPCTwith romiplostim support. Ro-
miplostimwas given subcutaneously at a dose of 250 mg on day of au-
tologous PBPC reinfusion. Twelve patients (median age, 39 years;
range 19-64; 6 male and 6 female) with NHL (n 5 6), HD (n 5 5)
and MM (n 5 1) were enrolled in the control group (without romi-
plostim). The end points of this study were the times of plateletsrecovery (TPR), the duration of thrombocytopenia, and the duration
of hospitalization.
Statistical analysis: Variable comparisons were evaluated by non-
parametric statistical methods (Mann-Whithey U test for continu-
ous variables and Fisher exact and Chi-square tests for categorical
variables).
Results:The duration of thrombocytopenia grade III was 10.7 days
in the romiplostim and 19.0 days in the control group (p 5 0.044).
The duration of thrombocytopenia grade IV was 6.9 and 13.8 days
in average groups, resp. (p 5 0.259). TPR grade III was 13.9 days
for romiplostim group and 22.2 days for control group (p 5
0.044). TPR grade IV was 13.0 and 18.7 days according to study
groups (p 5 0.035). The duration of hospitalization was 27.9 in
the romiplostim and 36.7 days in the control group (p 5 0.021).
Conclusion: This study demonstrates a tendency that the duration
of thrombocytopenia and hospital stay, the times of platelet recovery
are shortened when romiplostim is administered after HDT and
PBPCT. It seems highly likely that the use of romiplostim in setting
of autologous transplants improves clinical course of patients under-
going HDT.299
CMX001 IN THE PERI-ENGRAFTMENT PERIOD DOES NOT IMPAIR NEU-
TROPHIL RECOVERY IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC
STEM CELL RECIPIENTS
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Kumar, A.1, Jordan, M.B.1, Edwards, S.L.1, Kennedy, R.1, Wilhelm, J.1,
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Davies, S.M.1 1Cincinnati Children’s Hospital Medical Center, Cincin-
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Background: Double stranded DNA viruses (dsDNA) viral infec-
tions continue to be a significant cause of morbidity andmortality af-
ter allogeneic hematopoietic stem cell transplantation (HSCT).
These include cytomegalovirus (CMV), Epstein-Barr virus (EBV),
Adenovirus (ADV), Human Herpes Virus-6 (HHV-6) and BK virus
(BK). Currently available antiviral therapy has variable efficacy and,
more importantly, is associated with significant hematologic and re-
nal toxicities. CMX001, an orally bioavailable lipid conjugate of ci-
dofovir, is under investigation for the prevention and treatment of
these dsDNA viruses. Clinical data concerning the use of CMX001
for treatment of ADV andCMVhave been reported. However, there
is limited information available on the use of CMX001 prior to en-
graftment in allogeneic HSCT recipients.
Methods:We report on 4 patients with dsDNA viruses treated with
CMX001 prior to engraftment after allogeneic HSCT. The median
age was 2.1 years (Range 0.5 to 9.8). The preparative regimen con-
sisted of Alemtuzumab, Fludarabine andMelaphalan for all patients.
All patients had received first-line antiviral therapy (Ganciclovir, Fo-
scarnet or Cidofvoir) before starting on CMX001. Virologic re-
sponse (VR) was defined as 99% drop from baseline or
